Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Circulating levels of endocannabinoids and oxylipins altered by dietary lipids in older women are likely associated with previously identified gene targets☆,☆☆
Introduction
Postmenopausal women (PMW) are at a risk of excessive bone loss, hypertension, and metabolic syndrome. Moreover, while n − 3 polyunsaturated fatty acids (PUFA) status generally increases with age [1], PMW typically have marginal intakes of n − 3 PUFA. Stark et al. [2] reported that short-term supplementation with n − 3 PUFA (20:5n3 EPA and 22:6n3 DHA) in PMW resulted in similarly higher EPA and DHA levels and lower linoleic acid levels that correspond to Inuit women but not the markedly lower level of arachidonic acid (AA) seen in these seal eating populations. A recent investigation revealed that aerobic exercise and n − 3 PUFA supplementation with fish oil had a synergistic action on reducing inflammation and improving bone mineral density associated with osteoporosis in PMW [3].
While the specific mechanisms for the observed health improvements of n − 3 PUFA are still being explored, hypotriglyceridemia [4], improved ratios of LDL/HDL [5], and reductions in coronary artery disease progression [6] and atherosclerosis incidence in PMW [7] are well documented. As n − 3 PUFA are precursors for many biologically active metabolites, including endocannabinoids (ECs) and oxylipins (OLs), a key to understanding their health promoting properties is to identify how dietary n − 3 PUFA influence the production of these metabolites.
Although the role of the endocannabinoid system (ECS) has yet to be characterized in PMW, this system affects food intake and energy metabolism in peripheral tissues, and ECS overstimulation contributes to obesity and loss of insulin sensitivity in muscle. Consequences of elevated AA-derived EC, include overstimulating of the ECS [8] leading to impaired glucose uptake in skeletal muscle [9], stimulating osteoclast proliferation [10], and generating pro-inflammatory cyclooxygenase (COX)-derived prostanoids [11]. Thus, the impact of dietary PUFA on physiology likely include mechanisms associated with alterations in lipid mediator tone. Recently, our laboratory reported that n − 3 PUFA alter expression of several genes associated with the ECS in myoblasts [12] and the mouse [13] to influence glucose uptake and fat accretion, respectively. These observations are a reason to investigate n − 3 PUFA effects on ECs and OLs in PMW.
The OLs are oxygenated fatty acids that are important regulators of physiology and health and include metabolites of all PUFA, whose balance can be altered by dietary lipid content [14]. The 20-carbon “eicosanoids” are OL derived from AA or EPA metabolized by a suite of enzymes including various cyclooxygenases, lipoxygenases, and cytochrome P450 (CYPs) hydroxylase and epoxygenases. The COX- and LOX-derived OLs consist of prostanoids, thromboxanes, and leukotrienes, and mid-chain alcohols including hydroxyeicosatetraenoic acids [15], while the CYPs yield the vasoactive and immunomodulatory omega-hydroxy and -epoxy fatty acids [16]. Several other OLs are derived as secondary products of these metabolites, further adding to the potential fates of PUFA. Pertinent to PMW, prostaglandin E2 (PGE2) has been found to be a potent stimulator of bone resorption and regarded as the primary prostaglandin affecting bone metabolism [17]. Leukotriene B4 (LTB4) has also been found to increase bone resorption and affect osteoclast cell division. PGE2 and LTB4 are both AA metabolites which can be altered by dietary n − 6/n − 3 PUFA balance [18], further elaborating the influence of dietary PUFA on biological processes where OLs are involved. A well-accepted effect in response to n − 3 PUFA supplementation is the enrichment of membrane phospholipids with the long-chain n − 3 PUFA, EPA and DHA. Given the relationship between dietary and tissue PUFA and the potential effects on circulating EC and OL levels, our research aim was to determine how dietary PUFA alter plasma levels of these metabolites in the elderly. However, little is known about the EC and OL serum levels in older adults and PMW. Therefore, the primary hypothesis for this research is that dietary PUFA determine blood and tissue concentrations of AA, while n − 3 PUFA EPA and DHA decrease AA to alter the types of EC and OL in blood. In the current study, postmenopausal subjects were given an n − 3 PUFA supplement or placebo for 6 mo after which serum and plasma was collected to measure EC, OL, and PUFA, respectively. We also examined the effect of the n − 3 PUFA supplement on global metabolites (GM) influenced by changes in ECs and systemic macronutrient metabolism [8], [9]. The justification for this investigation with EPA and DHA is to determine the effects on the EC in PMW prior to studies on genes (cannabinoid receptors CB1 and CB2, GLUT 1, and insulin-R) related to these compounds which was shown in myoblast cultures and mice (protein expression of CB1, CB2, GLUT 4 and insulin-R) [12], [13].
Section snippets
Subjects, dietary supplements, and blood samples
Women with a mean age of 75 y (Table 1) were randomized in a double-masked manner to receive either 1.2 g EPA + DHA from fish oil (n = 20; 2 - 1 g capsules/d, 360 mg EPA and 240 mg DHA/capsule; Vital Nutrients, Middletown, CT) or olive oil placebo (n = 20; 2 capsules/d, 1.8 g oleic acid/d, Vital Nutrients). Blood samples (serum and plasma) were collected at baseline and 6 mo into the intervention period, kept on ice during collection and stored at − 80 °C, with sub-aliquots designated for the analysis of total
Plasma fatty acids
At baseline there were no differences in plasma fatty acid levels between the placebo and n − 3 PUFA groups. Supplementation with n − 3 PUFA to PMW for 6 mo resulted in higher 20/22-carbon n − 3 PUFA, and lower 22 carbon n − 6 PUFA in plasma (Table 2). A notable change was in higher plasma EPA, DHA, total n − 3 PUFA and ratio of DHA/AA, but lower ratio of n − 6/n − 3 PUFA and LC n − 6/n − 3 PUFA in the PMW group after 6 mo of n − 3 PUFA supplementation (Table 2). When compared between the placebo and n − 3 PUFA
Discussion
Supplementation of n − 3 PUFA (fish oil) to PMW led to their increase in the plasma as well as a change in the composition of the serum glycerolipids. These changes also resulted in a shift in the serum phospholipid pool, resulting in lower AA - but higher DHA-containing glycerolipids as reported in 2013 [32]. Specifically, 1-arachidonoylglycerophosphoinositol was lower while the DHA-derived 1-docosahexaenoylglycerophosphocholine, 2-docosahexaenoyl-glycerophosphocholine and
Conflict of interest
The authors have no conflict of interest to report.
Transparency document
Acknowledgements
Watkins organized the research, performed the FAME analyses and did most of the writing; Kenny collected samples and supervised the human study; Kim conducted the analyses of endocannabinoids and oxylipins under the supervision of Pedersen and Newman; Pappan performed the global metabolite analyses and data analysis was performed by Newman, Watkins and Pappan. All authors reviewed and help revise the manuscript. This research was supported by funds to BAW for the metabolomics collaborations at
References (57)
- et al.
Erythrocyte omega-3 fatty acids increase and linoleic acid decreases with age: observations from 160,000 patients
Prostaglandins Leukot. Essent. Fat. Acids
(2013) - et al.
Fatty acid compositions of serum phospholipids of postmenopausal women: a comparison between Greenland Inuit and Canadians before and after supplementation with fish oil
Nutrition
(2002) - et al.
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study
Clin. Ther
(2007) - et al.
Fish intake is associated with a reduced progression of coronary artery atherosclerosis in postmenopausal women with coronary artery disease
Am. J. Clin. Nutr
(2004) - et al.
Fat to treat fat: emerging relationship between dietary PUFA, endocannabinoids, and obesity
Prostaglandins Other Lipid Mediat
(2013) - et al.
Oxylipin metabolism in response to stress
Curr. Opin. Plant Biol
(2002) - et al.
Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function
Prog. Lipid Res
(2004) - et al.
Bioactive fatty acids: role in bone biology and bone cell function
Prog. Lipid Res
(2001) - et al.
Cox-2 expression, PGE(2) and cytokines production are inhibited by endogenously synthesized n − 3 PUFAs in inflamed colon of fat-1 mice
J. Nutr. Biochem
(2011) - et al.
Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to high-dose n3-HUFA in healthy volunteers
J. Lipid Res
(2012)
Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters
J. Lipid Res
Decoding functional metabolomics with docosahexaenoyl ethanolamide (DHEA) identifies novel bioactive signals
J. Biol. Chem
Actions of N-arachidonyl-glycine in a rat neuropathic pain model
Neuropharmacology
Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain
J. Biol. Chem
Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes
Biochim. Biophys. Acta
Prostaglandin synthesis in rat adrenocortical cells
J. Lipid Res
Lipid composition of subcellular particles of human blood platelets
J. Lipid Res
22-Carbon polyenoic acids. Incorporation into platelet phospholipids and the synthesis of these acids from 20-carbon polyenoic acid precursors by intact platelets
J. Biol. Chem
Effect of dietary supplementation with a fish oil concentrate on the alkenylacyl class of ethanolamine phospholipid in human platelets
J. Lipid Res
Interference of eicosapentaenoic and docosahexaenoic acids with arachidonate-and U46619-induced platelet activation and desensitization
Biochem. Pharmacol
Metabolism of 7,10,13,16-docosatetraenoic acid to dihomo-thromboxane, 14-hydroxy-7,10,12-nonadecatrienoic acid and hydroxy fatty acids by human platelets
Biochim. Biophys. Acta
Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception
Prostaglandins Other Lipid Mediat
The impact of supplemental n − 3 long chain polyunsaturated fatty acids and dietary antioxidants on physical performance in postmenopausal women
J. Nutr. Health Aging
Long-term aerobic exercise and omega-3 supplementation modulate osteoporosis through inflammatory mechanisms in post-menopausal women: a randomized, repeated measures study
Nutr. Metab. (Lond.)
Fish and omega-3 fatty acid intake and risk of coronary heart disease in women
JAMA
Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women
Circulation
Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle
Diabetologia
Peripheral cannabinoid receptor, CB2, regulates bone mass
Proc. Natl. Acad. Sci. U. S. A.
Cited by (31)
A Walnut-Enriched Diet for 2 Years Changes the Serum Oxylipin Profile in Healthy Older Persons
2024, Journal of NutritionLipid mediators of cerebrospinal fluid in response to TBE and bacterial co-infections
2023, Free Radical Biology and MedicineRole of cytochrome P450-epoxygenase and soluble epoxide hydrolase in the regulation of vascular response
2023, Advances in PharmacologyPlasma and serum oxylipin, endocannabinoid, bile acid, steroid, fatty acid and nonsteroidal anti-inflammatory drug quantification in a 96-well plate format
2021, Analytica Chimica ActaCitation Excerpt :As a class oxylipins and NAEs/NAGs had lower average LODs of ∼0.6 and ∼0.1 nM, respectively, while bile acids and steroids were higher with average LODs between 1 and 2 nM. The described method is comparable to similar methods using larger sample volumes, more extensive sample cleanups, and/or more targeted assays [2,16–21,36,37]. It should be noted that derivatization can be used to improve the LC-MS/MS sensitivity of some analytes.
- ☆
An abstract (#616.7) of this work was presented at the 2013 Experimental Biology Meeting at Boston, MA.
- ☆☆
Metabolomics collaborations at the University of Connecticut, Storrs and the UCHC, Center on Aging. Additional support was provided by the USDA Intramural Projects 5306-51530-019-00D and the West Coast Metabolomics Center Grant NIH U24 DK097154.